Default company panoramic image
New 20logo

ViroCarb Inc.

A new approach for prevention and treatment of HIV/AIDS

  • Stage Product In Development
  • Industry Biotechnology
  • Location Toronto, ON, Canada
  • Currency CAD
  • Founded April 2011
  • Employees 4
  • Incorporation Type C-corp
  • Website

Company Summary

ViroCarb is advancing innovative drugs to treat viral infections with unmet therapeutic need; our new series of small molecule inhibitors, developed in collaboration with lead academic collaborators in molecular genetics, functional genomics and medicinal chemistry, from the Universities of Toronto, British Columbia and Sherbrook, comprises compounds that target viral RNA processing to block the replication of important pathogenic viruses


  • Default avatar
    Dr. Mario Huesca
    Co-founder & President/Chief Operating Officer

    More than 15 years’ experience in management of industrial R&D programs and in the discovery and development of novel small molecule therapeutics. Led the discovery and development of several drug candidates currently in preclinical and clinical stages. Dr. Huesca obtained degrees in Pharmaceutical Chemistry and Pharmacology from the University of Mexico (UNAM) and a PhD in Molecular Genetics and Microbiology from the University of Toronto.

  • Default avatar
    Dr. Clifford Lingwood
    Co-founder& Chief Scientific Officer

    Former co-founder of Select Therapeutics (successful NASDAQ exit); Sr. Scientist, the Hospital for Sick Children and Professor at the University of Toronto. PhD degree from the University of London, England. Published over 200 original scientific papers and numerous patents. Dr. Lingwood is a world leader in research on receptor function of glycosphingolipids, including their role in HIV attachment and fusion with human immune cells.

Previous Investors

  • Default avatar
    Private investors
    Default avatar
    Mario Huesca